Share on StockTwits

Analysts at HC Wainwright began coverage on shares of Celator Pharmaceuticals (NASDAQ:CPXX) in a research report issued to clients and investors on Friday, reports. The firm set a “buy” rating and a $7.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 155.47% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated an “outperform” rating on shares of Celator Pharmaceuticals in a research note on Friday, August 8th. They now have a $7.00 price target on the stock.

Shares of Celator Pharmaceuticals (NASDAQ:CPXX) traded up 2.19% during mid-day trading on Friday, hitting $2.80. The stock had a trading volume of 9,345 shares. Celator Pharmaceuticals has a 52 week low of $2.04 and a 52 week high of $6.00. The stock has a 50-day moving average of $2.70 and a 200-day moving average of $2.88. The company’s market cap is $73.0 million.

Celator Pharmaceuticals (NASDAQ:CPXX) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.18) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.20) by $0.02.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.